Introduction
Hypertensive heart disease manifest by left ventricular hypertrophy remains a potent and independent risk factor for cardiovascular disease. This is particularly evident for the clinical syndromes associated with coronary artery disease.
The presence of ECG LVH is associated with an increase in all cause mortality by a factor of 4 and cardiovascular mortality by a factor of 7 in men and 9 in women [1] . The age-adjusted risk of sudden cardiac death (SCD) is also increased by a factor of 7 in men with ECG evidence of LVH, somewhat surprisingly this effect is not seen in women [2] . These facts have stimulated considerable research in the prevalence, prognostic importance and treatment of ventricular arrhythmias in hypertensive heart disease (HHD). Studies have revealed an increase in atrial arrhythmias, ventricular ectopy and non-sustained ventricular tachycardia (VT) but despite this there remains no clear link between the presence of these dysrhythmias and SCD.
Incidence of Arrhythmias and Syncope in Hypertension
There have been many descriptive studies documenting dysrhythmias in patients with LVH. Messerli et al. were~rst to demonstrate a marked increase in ventricular arrhythmias and a smaller, but signi~cant increase in atrial arrhythmias in hypertensive patients with LVH [3] .
This original work has been validated by a number of studies. Pringle et al. demonstrated an increase in the frequency of ventricular arrhythmias in patients with ECG LVH and strain. It should be noted that the rate of non-sustained VT was low. Sustained VT was not noted in any patient and programmed ventricular stimulation was unsuccessful in inducing sustained VT in the same cohort [4, 5] . Mclenachan et al. reported non-sustained VT in 8% of hypertensives without ECG LVH and 28% of hypertensives with ECG LVH and strain [6] . Studying a group of untreated hypertensives, James et al. demonstrated both an increase in atrial arrhythmias and ventricular arrhythmias but no relationship to LVH [7] . This is in contrast to most of the published work which shows a signi~cant increase in the prevalence and frequency of dysrhythmias in the presence of LVH. In fact Ghali et al. demonstrated a graded relationship between ventricular arrhythmias and LVH assessed by echocardiography in patients with normal coronary arteries. For every 1 mm increase in wall thickness there was a corresponding increase in the occurrence and complexity of ventricular arrhythmias [8] .
Novo et al. studied a group of hypertensives who were dichotomised into groups with and without LVH. The group with LVH had a signi~cant increase in the presence of supraventricular and ventricular dysrhythmias with 12% of patients having runs of non-sustained VT. The occurrence of VT was signi~cantly related to both heart rate and ambulatory systolic pressure [9] . Consistently similar rates of ventricular arrhythmias are reported in studies where similar cohorts are investigated.
Atrial arrhythmias have been documented by several groups although the incidence appears more variable than that of ventricular arrhythmias in the same setting. Nikulin et al. reported atrial arrhythmias in 82.4% of a cohort of 57 males with HHD [10] . Whilst Novo reported rates of 36.4% for the presence of supraventricular couplets and lower rates for the presence of supraventricular tachycardia. Additionally Nikulin reported a correlation between left atrial size and the occurrence of atrial~brillation however notably no relationship with LVH.
Syncope has been reported to be a presenting symptom in elderly hypertensives with transient ischaemic attacks [11] . Most reports of syncope remain related to the effects of anti-hypertensive therapy rather than the occurrence of symptomatic arrhythmias [12] .
Possible Mechanisms for Arrhythmias in Hypertension
Various mechanisms have been put forward for the presence of cardiac arrhythmias in patients with hypertension. Firstly an increment in blood pressure has been shown to lower electrical thresholds and may facilitate spontaneous depolarisation secondary to in-creased wall stress which alters the permeability of the cell membrane [13] . Studies have demonstrated that the frequency of ventricular ectopy is related to the blood pressure.
There are a number of electrophysiological abnormalities described in the hypertrophied myocyte. Aronson demonstrated in hypertrophied rat myocytes an increase in the duration of the action potential, a decrease in the effective membrane capacity and susceptibility to develop calcium dependent afterpotentials. He also demonstrated evidence of triggered activity as a result of these afterpotentials. These electrophysiological changes were not shown to be uniform throughout the myocardium [14, 15] .
Rials et al. demonstrated in the feline heart that cats with persistent LVH has a higher incidence of inducible polymorphic ventricular tachycardia and lower ventricular~brillation thresholds, compared with cats without LVH. Persistent LVH was associated with elongation of the epicardial monophasic action potential in the left ventricle. Cats that showed regression of hypertrophy had normal ventricular electro-physiology and the same low vulnerability to inducible arrhythmias as control animals [16] . Regression of LVH in this study involved removal of the aortic banding. This is an arti~cial situation which has few parallels in human hypertension where the cause of LVH can rarely be surgically removed. Rials therefore repeated this study in a more clinically relevant fashion. Using a rabbit model, hypertension was induced by renal artery banding and contralateral nephrectomy. There was also a sham operated control group. Three months following this intervention, Captopril or placebo was added to the rabbits feed. The captopril treated group showed regression of LVH, normalisation of action potential duration, normalisation of dispersion of refractoriness and decreased vulnerability to inducible VF. Electrical abnormalities persisted in the isolated hypertrophied myocyte thus suggesting no direct antiarrythmic effect of Captopril [17] . Taking these results in context it would appear that it is the process of regression of LVH which normalises the electrophysiological abnormalities and that any intervention which results in regression of LVH will normalise ventricular electrophysiology.
A raised QT dispersion, which is associated with an increase in sudden cardiac death, has been demonstrated in left ventricular hypertrophy and hypertension [18] . Trials using ACE inhibitors and Angiotensin II receptor antagonists have shown a normalisation of the QT dispersion with treatment [19, 20] which appears to be independent of any antihypertensive effect.
In addition to myocyte hypertrophy the hypertrophic process results in an interstitial~brosis. This process is not a load dependent phenomena and is under neurohormonal control. Fibrosis has a number of features that may facilitate the occurrence of reentry arrhythmias. Fibrosis creates heterogeneity within the myocardium modifying the local refractory periods and generally slowing conduction [21] . Inter-ventricular conduction is delayed leading to the appearances of late potentials which are predictive of ventricular tachyarrhythmias [22] . Barriers of~brous tissue fragment the ventricular excitation wave front facilitating re-entrant arrhythmias and~nally~brosis contributes further to the ischaemia of the hypertrophied myocardium.
Myocardial ischaemia is a central mechanism for the occurrence of ventricular arrhythmias. Ischaemia occurs in the presence of left ventricular hypertrophy even in the absence of obstructive coronary disease. Demonstrable ischaemia on holter monitoring can occur in up to 40% of patients with LVH [23] . Hypertensive patients with a Thallium defect have a 48% risk of developing angina, SCD or MI compared with 7% in patients with a normal Thallium scan [24] . The importance of co-existent ischaemia is further demonstrated by Aronow who reported that 22% of patients with VT and ischaemia on holter monitoring developed a cardiac event whilst only 8% of the group with VT alone suffered an event. They calculated that hypertensive patients with silent ischaemia and LVH have a 60% risk of a cardiac event [25] .
Furthermore recent analyses of the LIFE cohort demonstrated that hypertensive patients with LVH but without overt evidence of epicardial or microvascular disease had no demonstrable late potentials or ventricular arrhythmias [26] . Finally the development of left ventricular systolic or diastolic dysfunction, persistent activation of the renin angiotensin system and antihypertensive therapy are contributory factors in the development of arrhythmias in patients with hypertension and LVH.
Management Strategies
Antiarrhythmic therapy has no role in the current management of hypertensive heart disease since there is no evidence demonstrating that the ventricular arrhythmias in these patients are a factor predisposing to sudden cardiac death. The CAST trial clearly has demonstrated the dangers inherent in the prescription of antiarrhythmic therapy, particularly in the setting of ischaemic heart disease [27] .
In hypertension the treatment should be aimed at effective blood pressure control and associated regression of LVH. ACE-inhibitors appear to be particularly effective in the regression of LVH. Studies with ACE inhibitors in animal models have shown regression of left ventricular hypertrophy to be associated with restoration of normal action potential duration, dispersion of refractoriness and vulnerability to inducible VF [17] . However it would appear to be the process of regression of LVH that results in the normalisation of the electrophysiological abnormalities rather than any speci~c effect of an individual therapy. This hypothesis is supported by the fact that diuretics, beta blockers
